We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+20.93%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$952M
AUM Growth
+$119M
Cap. Flow
-$4.06M
Cap. Flow %
-0.43%
Top 10 Hldgs %
45.23%
Holding
168
New
60
Increased
16
Reduced
31
Closed
41

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$23.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$16.8M
4
TVTX icon
Travere Therapeutics
TVTX
+$16.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$48M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.8M
3
MNKD icon
MannKind Corp
MNKD
+$19.8M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.36%
2 Miscellaneous 16.85%
3 Consumer Staples 1.74%
4 Technology 0.04%
5 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
51
AbbVie
ABBV
$465B
$3.44M 0.36%
67,000
-283,000
-81% -$14.3M
ALNY icon
52
Alnylam Pharmaceuticals
ALNY
$31.9B
$3.36M 0.35%
+50,000
New +$3.87M
ITMN
53
CALL
DELISTED
INTERMUNE INC
ITMN
$3.35M 0.35%
+100,000
New +$2.23M
GRCE
54
Grace Therapeutics
GRCE
$46.9M
$3.3M 0.35%
5,978
-3,167
-35% -$1.93M
CMRX
55
DELISTED
Chimerix, Inc.
CMRX
$3.2M 0.34%
140,000
-10,000
-7% -$202K
FPRX
56
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.95M 0.31%
150,000
+17,500
+13% +$297K
VXRT
57
DELISTED
Vaxart
VXRT
$2.54M 0.27%
+37,727
New +$2.33M
VSTM icon
58
Verastem
VSTM
$665M
$2.39M 0.25%
18,333
– –
TNDM icon
59
Tandem Diabetes Care
TNDM
$1.13B
$2.34M 0.25%
10,590
-1,970
-16% -$502K
MGCD
60
DELISTED
MGC Diagnostics Corporation
MGCD
$2.31M 0.24%
206,957
+27,338
+15% +$309K
ATHX
61
DELISTED
Athersys, Inc. Common Stock
ATHX
$2.27M 0.24%
28,063
-39,972
-59% -$3.7M
GNVC
62
DELISTED
GenVec, Inc.
GNVC
$2.17M 0.23%
+82,000
New +$2.67M
ABUS icon
63
PUT
Arbutus Biopharma
ABUS
$1B
$2.15M 0.23%
+100,000
New +$1.8M
MDVN
64
DELISTED
MEDIVATION, INC.
MDVN
$2.05M 0.22%
+63,800
New +$2.35M
FOLD
65
DELISTED
Amicus Therapeutics
FOLD
$2M 0.21%
+966,300
New +$2.42M
ATRC icon
66
AtriCure
ATRC
$2.86B
$1.88M 0.2%
+100,000
New +$2.05M
UPI
67
DELISTED
UROPLASTY INC-NEW
UPI
$1.88M 0.2%
517,791
+203,802
+65% +$796K
OXGN
68
DELISTED
OXIGENE INC COM
OXGN
$1.86M 0.2%
+500,000
New +$1.39M
QCOR
69
DELISTED
QUESTCOR PHARMA INC
QCOR
$1.86M 0.2%
+28,600
New +$1.83M
IDIX
70
CALL
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$1.81M 0.19%
300,000
– –
CGEN icon
71
Compugen
CGEN
$228M
$1.79M 0.19%
+170,000
New +$1.87M
NGNE icon
72
Neurogene
NGNE
$674M
$1.66M 0.17%
+6,500
New +$1.67M
CASC
73
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.62M 0.17%
90,500
+7,167
+9% +$118K
BDSI
74
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.6M 0.17%
+190,000
New +$1.53M
ICAD
75
DELISTED
iCAD Inc
ICAD
$1.6M 0.17%
+175,000
New +$2M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Perceptive Advisors held 168 positions worth $952M, up 14% from $833M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors's Q1 2014 filing shows 60 new, 16 increased, 31 reduced and 41 closed positions. Its largest new stake was Heron Therapeutics: 1,762,426 shares worth $24.5M. The largest sale was Celgene Corp, an estimated $48M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q1 2014 buy was Heron Therapeutics: 1,762,426 shares worth $24.5M.
  • Perceptive Advisors added most to Clovis Oncology, Inc. in Q1 2014, an estimated $10.4M increase.
  • Perceptive Advisors's biggest Q1 2014 reduction was Celgene Corp, cutting an estimated $48M.
  • Perceptive Advisors fully exited Aegerion Pharmaceuticals in Q1 2014, selling an estimated $31.8M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $952M portfolio in Q1 2014.
  • Perceptive Advisors opened 60 new positions and closed 41 in Q1 2014.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $952M.

Based on Perceptive Advisors's 13F filing for Q1 2014, filed 15 May 2014.